Welcome to BioSeeker Group!

Market Development in Anti-virals:What is Next?

Additional Information

Published Date Aug 24, 2004
Pages 77
PDF Fact Sheet View Fact Sheet for the report Market Development in Anti-virals:What is Next? in PDF
Format PDF
Publisher BioSeeker Group

Availability: In stock

$495.00

Quick Overview

This analysis deals with 26 of the most promising pharmaceutical companies with anti-viral drugs on the market. Indication by indication is measured by number of current therapies, present sales and sales development.

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Market Development in Anti-virals:What is Next?.

    To find out more about Market Development in Anti-virals:What is Next?, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Market Development in Anti-virals:What is Next? is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

Executive Summary

There are huge unmet medical needs in viral infections. Any virus can become multi-resistant and a consequence of this is the constant need for new improved pharmaceuticals. The total anti-viral market is progressing well beyond $10bn and the prognosis for 2007 is that it will reach around $14bn. Surprisingly few companies share this sizeable global market, which can explain all the new entrants knocking on the door at this time. These comprise the full range of true innovators, "me better" to "me too".

There are more than 170 phase I drugs and close to 40 phase III drugs in development for different viral indications. Competition varies from fierce, as within the HIV market, to the seemingly unchallenged market of RSV. MedImmune’s RSV blockbuster drug Synargis scored close to a billion US in 2003. The competitive business environment for the pharmaceutical market of HCV infection is also fierce and changing. Hoffmann-La Roche’s entry into this $3 billion market, previously dominated by Schering-Plough, has certainly paved the way and will make life easier for other HCV drug developing companies. Competition is healthy, and market dominance by one big pharma provides far fewer business opportunities compared to two companies fighting to be the world leader.

A considerable proportion of all infectious diseases occur in densely populated countries in the process of rapid economic growth, such as parts of Southeast Asia and China. These areas will most likely become significant new markets for drugs against infections diseases over the coming decade.

This analysis deals with 26 of the most promising pharmaceutical companies with anti-viral drugs on the market. Indication by indication is measured by number of current therapies, present sales and sales development. BioSeeker Intelligence Unit has taken a closer look on second generation drugs following up existing ones and preferred viral R&D strategies. We have chosen also outlined the competitive landscape around market leaders such as GlaxoSmithKline, F-Hoffmann La Roche, Bristol-Myers Squibb and Gilead Sciences. Our analysis creates valuable insights in market and R&D development for all major viral infections, such as HIV, Hepatitis, HSV, and Influenza.

Executive Summary
Table of Contents
List of Figures
List of Tables
About BioSeeker Group
Our Five Steps to Creating Success in Intelligence
Databases
Reports
Analytical Tools
Consulting
Intelligence Partnership
Methodology
The Viral Market Outlook
Antiviral Submarket Development
HIV Market Development
Products on Market and Competing Companies
Sales and Sales Development
Hepatitis Market Development
Products on Market and Competing Companies
Sales and Sales Development
HSV Market Development
Products on Market and Competing Companies
Sales and Sales Development
Influenza Market Development
Products on Market and Competing Companies
Sales and Sales Development
Market Development of Other Submarkets
Products on Market and Competing Companies
Sales and Sales Development
Strategies and Targets for Future Viral Drug Discoveries
R&D Strategies Employed in Viral Drug Target Discovery
Strategy 1
Strategy 2
Strategy 3
Strategy 4
Strategy 5
Strategy 6
Strategy 7
The Competitive Landscape of Leaders
Do the major players R&D pipelines indicate a leader shift?
Conclusion
Disclaimer
Liability
Completeness
Company profiles:
Appendix A: The Current Anti-Viral Drug Portfolio
Appendix B: Global Inventory of Phase I Antiviral Drugs
Appendix C: Global Inventory of Phase II Antiviral Drugs
Appendix D: Global Inventory of Phase III Antiviral Drugs

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Market Development in Anti-virals:What is Next?.
    To find out more about Market Development in Anti-virals:What is Next?, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Market Development in Anti-virals:What is Next? is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

Other selected research from the 'Pharmacoeconomics' category:


Market Development in Anti-virals:What is Next?
This analysis deals with 26 of the most promising pharmaceutical companies with anti-viral drugs on the market. Indication by indication is measured by number of current therapies, present sales and sales development. Learn More

Other selected research from the 'R&D' category:


Targeting Tight Junctions in Cancer Drug Pipeline Update
BioSeeker Group have identified 120 companies plus partners who are today developing 122 tight junction targeting drugs in 466 developmental projects in cancer across 107 different targets. In addition, there is 1 suspended drug and another 48 drugs where development has been ceased. Learn More


T Cell Receptor Signaling Pathway in Oncology Drug Pipeline Update
BioSeeker Group have identified 355 companies plus partners who are today developing 469 T cell receptor pathway targeting drugs in 1756 developmental projects in cancer across 242 different targets. In addition, there are 7 suspended drugs and another 210 drugs where development has been ceased. Learn More

Other selected research from the 'Infectious diseases' category:


HCV R&D and Business Development Database
This CD-ROM product is one of the most comprehensive and up to date information sources on chronic hepatitis C virus R&D and business development. Learn More


Antifungals: 2004 and Beyond
Overview of the most common fungal diseases, already marketed antifungal agents, details from recent studies on approved agents, and information on the recent activities of companies with developmental antifungals. Learn More